1. The Chinese First-Episode Schizophrenia Trial: Background and Study Design.
- Author
-
Han, X., Yuan, Y. B., Yu, X., Zhao, J. P., Wang, C. Y., Lu, Z., Yang, F. D., Dong, H., Wu, Y. F., Ungvari, G. S., Xiang, Y. T., and Chiu, H. F. K.
- Subjects
- *
RISPERIDONE , *OLANZAPINE , *MOTOR ability , *RESEARCH methodology evaluation , *DECISION making , *ARIPIPRAZOLE , *AGE factors in disease , *BLOOD testing , *INTERVIEWING , *LONGITUDINAL method , *MEDICAL cooperation , *MEMORY , *QUESTIONNAIRES , *RESEARCH , *RESEARCH funding , *STATISTICAL sampling , *SCHIZOPHRENIA , *ADULT education workshops , *PHONOLOGICAL awareness , *RANDOMIZED controlled trials , *INTER-observer reliability , *THERAPEUTICS - Abstract
Schizophrenia is a complex illness with unknown aetiology and pathogenesis. Currently, a considerable number of patients with schizophrenia do not receive standardised and systematic treatment in China. In the past years, many controlled trials have been conducted in chronic schizophrenia. In contrast, research on first-episode schizophrenia is lacking. This paper describes the background and design of the Chinese First-Episode Schizophrenia Trial project — a multicentre, randomised, open-label clinical trial. A total of 600 first-episode schizophrenia patients were randomly divided into 3 groups and treated with risperidone, aripiprazole, and olanzapine for 1 year. During the study period, only 1 medication change of the 3 antipsychotic medications was allowed. [ABSTRACT FROM AUTHOR]
- Published
- 2014